ATRA
INSIDER BUYINSIDER SELLAtara Biotherapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeAtara faced a second FDA Complete Response Letter for tabelecleucel in 2026 due to unresolved GMP compliance issues, triggering a BLA resubmission in September 2026 via Pierre Fabre and resetting the regulatory timeline. The company is burning through minimal cash (~$9.9M, sufficient only to mid-2027), faces active securities fraud litigation tied to alleged misleading statements about the drug and manufacturing defects, and has seen analyst downgrades with price targets cut by over 50% amid deteriorating share price momentum.
Red flags
- •Second FDA Complete Response Letter for lead candidate (manufacturing/GMP compliance unresolved)
- •Revenue collapsed 97% YoY ($0.6M vs $17.6M) despite cost cuts
- •Cash position of $9.9M funds operations only to mid-2027 with no approved product revenue
- •Securities fraud class action ongoing (May 2024–Jan 2026 class period) alleging misstatements on approval likelihood and manufacturing issues
- •Additional shareholder litigation investigations announced (October 2026)
- •Analyst downgrades and 50%+ price target cuts
- •Stock trading below 50-day moving average ($8.82 vs $9.12 MA) in early October 2026
- •Board refresh focused on 'capital allocation and strategic acquisitions' signals potential M&A/restructuring necessity
Insider Activity
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).